AMPICILLIN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ampicillin sodium and what is the scope of patent protection?
Ampicillin sodium
is the generic ingredient in seven branded drugs marketed by Acs Dobfar Spa, Antibiotice, Apothecon, Consolidated Pharm, Eugia Pharma Speclts, Hikma, Hospira, Hq Speclt Pharma, Intl Medication, Istituto Bio Ita Spa, Lilly, Onesource Specialty, Sagent Pharms Inc, Sandoz, Watson Labs Inc, Wyeth Ayerst, Bristol, Glaxosmithkline, Acs Dobfar, Astral, Eurofarma, Hospira Inc, and Pfizer, and is included in fifty-six NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for ampicillin sodium. Sixteen suppliers are listed for this compound.
Summary for AMPICILLIN SODIUM
| US Patents: | 0 |
| Tradenames: | 7 |
| Applicants: | 23 |
| NDAs: | 56 |
| Drug Master File Entries: | 14 |
| Finished Product Suppliers / Packagers: | 16 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 13 |
| Patent Applications: | 3,178 |
| What excipients (inactive ingredients) are in AMPICILLIN SODIUM? | AMPICILLIN SODIUM excipients list |
| DailyMed Link: | AMPICILLIN SODIUM at DailyMed |
Recent Clinical Trials for AMPICILLIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The George Institute | PHASE3 |
| Ain Shams University | PHASE2 |
| M.D. Anderson Cancer Center | Phase 2 |
Pharmacology for AMPICILLIN SODIUM
| Drug Class | Penicillin-class Antibacterial |
Medical Subject Heading (MeSH) Categories for AMPICILLIN SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for AMPICILLIN SODIUM
US Patents and Regulatory Information for AMPICILLIN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 062860-002 | Feb 5, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sagent Pharms Inc | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 090581-001 | Oct 20, 2015 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Consolidated Pharm | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 061936-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch